Keefe Bruyette cuts Progressive stock price target on 2027 outlook By Investing.com

Keefe, Bruyette & Woods trimmed Progressive’s price target to $208 from $210 while keeping a Market Perform rating, raising its 2026 EPS estimate to $16.60 from $16.30 but lowering 2027 EPS to $17.30 from $17.50. The firm cited stronger premium and investment income growth as near-term offsets to higher core losses and share count, while other brokers remain mixed on the stock with targets ranging from $190 to $312. Progressive also reported first-quarter net premiums written of $23.64 billion, up 6%, and net income of $2.82 billion, up 10%.

Analysis

The read-through here is less about a single insurer print and more about the market being forced to reconcile a business with strong current-cycle pricing power against a slower-moving earnings multiple reset. For PGR, the key second-order effect is that higher investment income can now mask weaker underwriting elasticity for longer than the market historically allows, which tends to keep sell-side numbers too high on a 12-18 month lag. That creates a setup where the stock can look optically cheap on near-term earnings while still failing to de-rate up if reserve releases and premium growth normalize.

The analyst divergence is the real signal: the bull case is anchored on continued disinflation in cats and favorable float income, while the bear case is effectively a normalization call on profitability mix. That’s important because Progressive’s premium growth quality is already being tested by the higher share count and a rising core loss ratio, so any incremental upside from investment income is lower convexity than headline EPS suggests. In other words, the next leg is likely to come from underwriting surprise, not rates, and that is harder to sustain for multiple quarters.

From a broader sector lens, this is mildly positive for large-cap P&C insurers with cleaner balance sheets and more duration in invested assets, but less helpful for names whose bull thesis depends on reserve releases. The contrarian risk is that consensus is underestimating how long the market can reward visible earnings growth even when forward margins are mechanically flattening; if PGR continues to post mid-single-digit premium growth with stable combined ratios, the stock can remain range-bound but not cheap enough to force value buying. The more interesting trigger is a catalyst inversion: if investment income disappoints or premium growth slows in the next 1-2 quarters, the multiple could compress quickly because the current debate is already crowded and the dispersion across targets shows no coherent consensus.

Key Decisions for Investors

• Use any rally toward the high end of the analyst range to fade PGR via a 1-2 month call spread overwrite or outright tactical short against a basket of higher-quality P&C peers; reward/risk improves if the stock remains anchored near 12x forward earnings while estimates plateau.
• Pair long PGR / short a reserve-release-dependent insurer for a 3-6 month relative-value trade; the edge is better earnings durability if float income stays supportive, but cut the pair if underwriting margins weaken two quarters in a row.